Veea Inc. and NovaGen Group Announce Merger to Launch Edge AI Health Platform

Veea Inc., a provider of AI-powered, cybersecure edge infrastructure, and NovaGen Group B.V., a personalized regenerative medicine and longevity company, have signed a term sheet to combine and target the execution of a definitive business combination agreement within the coming weeks. The merger aims to launch NovaGen Health Networks, an edge AI-powered global health platform integrating Veea’s edge computing, connectivity, and cybersecurity capabilities with NovaGen’s cellular reprogramming science and clinical services.

The platform, built on VeeaONE, will connect health records, wearable and sensor data, and biological measurements into a patient-controlled longitudinal health profile. Local computing will support agentic AI applications close to the patient, with patient-directed permissions governing access to personal data. Initial deployments will begin at NovaGen clinics and partner hospitals in the fourth quarter of 2026.

GeoNova Capital, a cornerstone investor, has committed to provide an initial US$10 million investment in the combined company. Veea will continue to grow and serve its existing customers, partners, and markets. Management believes that, based on internal projections and an independent valuation, the value of the combined company is approximately $750 million.

The business combination and the investment by GeoNova Capital remain subject to the negotiation and execution of definitive documentation and the satisfaction of certain conditions to closing by the parties. The companies plan to roll out NovaGen Health Networks in two phases.

In the first phase, NovaGen Health Networks will provide a private household health hub with a digital twin for every family member and a patient-controlled health records wallet. The hub will integrate health records, wearable telemetry, and longitudinal biological measurements. Built on VeeaONE, the hub will process sensitive data locally and support AI wellness companions, medication reminders, and patient-authorized provider sharing. Plans include personal cell banking and consented research participation, subject to applicable regulatory requirements.

In the second phase, as clinical validation and regulatory authorizations permit, the network will combine digital twins and medical records with cellular data from the small skin biopsy used to initiate the ARC Prometheus process. This biopsy provides a patient's own fibroblasts for cellular reprogramming, rejuvenation, cell banking, and potential future autologous therapies. Telomere length, DNA-methylation age, and additional biomarkers will be assessed to support clinician evaluation of therapy candidates and treatment monitoring. Validated AI tools will support clinician-reviewed decisions and referrals to authorized treatment centers.

Diederik van der Reijt, CEO of NovaGen Group, stated, "NovaGen is a regenerative medicine platform with proprietary autologous rejuvenated fibroblast stem cell technology and a growing network of associated clinics. This agreement with Veea extends our reach to individuals long before they walk into a clinic. NovaGen Health Networks creates a pathway to identify and evaluate potential candidates for our therapies, allowing that relationship to begin earlier and continue through assessment, treatment, and follow-up, including the creation of each patient's own digital twin."

Patient privacy and data sovereignty are central to the network's design. Health records remain encrypted at source and off the blockchain; the blockchain ledger records only permissions, document fingerprints, and access events. Patients authorize specific recipients, categories of information, and access periods, and may revoke access at any time. Cloud services use pseudonymous digital twins, with re-identification controlled through protected keys and authorized consent. Veea's cybersecurity architecture, incorporating Zero Trust Network Access, network slicing, micro-segmentation, and AI-driven anomaly detection, protects the network end-to-end.

Robert Hamilton, Managing Partner, Capital Markets, GeoNova Capital, commented, "GeoNova's US$10 million commitment reflects our conviction in NovaGen's strategy and the scale of the opportunity. As corporate adviser and cornerstone institutional investor, our role is to support NovaGen with institutional capital, capital-markets discipline, and strategic execution as it advances toward the U.S. public markets."

Veea Inc. (NASDAQ: VEEA) is a global leader in edge solutions and infrastructure, founded in 2014 and headquartered in New York City. The company enables enterprises, service providers, and public sector organizations to deploy AI-powered applications at the edge. The VeeaONE platform integrates connectivity, computing, cybersecurity, and storage into a unified hyperconverged network solution, from edge to cloud. Veea holds more than 123 patents across related technology domains and has been recognized by Gartner for its innovations in edge computing.

NovaGen Group has developed a personalized regenerative medicine and longevity platform integrating ARC Prometheus cellular reprogramming and rejuvenation technology, biological assessment, cell banking, clinical services, and digital health. Its strategy connects research and clinical development with a growing network of care locations and partners to support more personalized approaches to health and aging.